This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Biotest AG

Drug Names(s): Altastaph

Description: Altastaph is an investigational human antibody-based product containing high levels of antibodies to capsular polysaccharides (protective outer coatings on S. aureus bacteria) from S. aureus types 5 and 8, which together account for approximately 85% of all S. aureus infections. These antibodies are the same antibodies that are developed in patients who are vaccinated with StaphVAX(R) (Staphylococcus aureus polysaccharide conjugate vaccine), Nabi Biopharmaceuticals' investigational vaccine to prevent S. aureus infections. Altastaph is being developed to provide short-term, immediate protection to patients, such as neonates, who are at high risk of S. aureus infection because of the invasive procedures that they face while their immune systems are still underdeveloped. It may also have a role in treating other immune compromised patients who cannot respond effectively to a vaccine such as StaphVAX. Altastaph is manufactured in the company's Boca Raton, Florida, manufacturing facility.

Altastaph, the second in Nabi's portfolio against Gram-positive infections, is an investigational human immune globulin product enriched in antibodies to S. aureus type 5 and type 8 CPS. Altastaph is purified from the plasma of healthy donors that have been vaccinated with StaphVAX. Altastaph is being developed to provide short-term protection from S. aureus in trauma patients and others at immediate risk of infection, where a vaccine would not have time to take effect.

Deal Structure: In September 2007, Nabi Biopharmaceuticals announced that it had entered into a definitive agreement with Biotest AG to sell the Nabi Biologics strategic business unit (SBU) to Biotest Pharmaceuticals Corporation for $185 million. The acquisition of Biologics SBU's products includes Nabi-HB, Civacir, and Altastaph. Nabi will retain its Pharmaceuticals strategic business unit assets, including NicVAX and its investigational StaphVAX programs.

In December 2007, Biotest completed its acquisition of Nabi's Biologics strategic business unit.

Altastaph News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug